Copyright
©The Author(s) 2023.
World J Clin Oncol. Dec 24, 2023; 14(12): 606-619
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Figure 6 Disease monitoring during therapy by evaluating cerebrospinal fluid circulating tumor DNA.
A: P8; B: P3. PR: Partial response; SD: Stable disease; P8: Patient 8; P3: Patient 3.
- Citation: Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619
- URL: https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i12.606